WHO ending hydroxycholorquine trial for COVID

World News

Circus troupe member Alexandra “Calabacita” Suarez, receives donated vegetables in Bogota, Colombia, Saturday, July 4, 2020. The donations are then used by the “Circo Encuentro” troupe members to prepare a “sopita de murcielago” or bat soup community kitchen style in a selected neighborhood where residents have been economically affected by the COVID-19 related shutdowns. (AP Photo/Fernando Vergara)

BERLIN — The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalized with COVID-19.

WHO said Saturday it has “accepted the recommendation” from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.”

The agency adds that while there was no “solid evidence” of increased mortality for hospitalized patients given the drugs, there were “some associated safety signals in the clinical laboratory findings” of an associated trial.

WHO says the decision won’t affect possible trials on patients who aren’t hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Food Drive
Destination Vacation
Livin Upstate Deals
Carolina Eats Contest
Adopt A Thon
wspa news app free for download choose your store below
download the wspa news app from the apple app store
download the wspa news app from the google play store

Trending Stories